SCYNEXIS, Inc. (SCYX)
USD 1.03
(4.42%)
USD 1.03
(4.42%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 72.66 Million USD | 184.74% |
| 2022 | -85.75 Million USD | -40.99% |
| 2021 | -60.82 Million USD | -18.92% |
| 2020 | -51.14 Million USD | -4.55% |
| 2019 | -48.92 Million USD | -63.16% |
| 2018 | -29.98 Million USD | -13.92% |
| 2017 | -26.32 Million USD | 5.38% |
| 2016 | -27.81 Million USD | 1.88% |
| 2015 | -28.34 Million USD | -93.55% |
| 2014 | -14.64 Million USD | -103.32% |
| 2013 | -7.2 Million USD | 7.45% |
| 2012 | -7.78 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -9.5 Million USD | 58.78% |
| 2024 Q2 | -9.23 Million USD | 2.85% |
| 2023 Q2 | 116.51 Million USD | 1190.75% |
| 2023 Q1 | -10.68 Million USD | 52.48% |
| 2023 FY | 72.66 Million USD | 184.74% |
| 2023 Q4 | -23.06 Million USD | -128.41% |
| 2023 Q3 | -10.09 Million USD | -108.67% |
| 2022 Q3 | -21.8 Million USD | -0.29% |
| 2022 Q4 | -22.48 Million USD | -3.12% |
| 2022 Q1 | -19.73 Million USD | 11.48% |
| 2022 FY | -85.75 Million USD | -40.99% |
| 2022 Q2 | -21.73 Million USD | -10.13% |
| 2021 Q2 | -17.5 Million USD | -998.37% |
| 2021 Q1 | -1.59 Million USD | 89.61% |
| 2021 Q4 | -22.29 Million USD | -14.69% |
| 2021 Q3 | -19.44 Million USD | -11.04% |
| 2021 FY | -60.82 Million USD | -18.92% |
| 2020 Q2 | -11.82 Million USD | 5.23% |
| 2020 Q3 | -11.51 Million USD | 2.66% |
| 2020 Q4 | -15.33 Million USD | -33.24% |
| 2020 FY | -51.14 Million USD | -4.55% |
| 2020 Q1 | -12.47 Million USD | 11.54% |
| 2019 FY | -48.92 Million USD | -63.16% |
| 2019 Q1 | -11.86 Million USD | -34.94% |
| 2019 Q3 | -11.75 Million USD | -5.0% |
| 2019 Q4 | -14.1 Million USD | -20.0% |
| 2019 Q2 | -11.19 Million USD | 5.61% |
| 2018 FY | -29.98 Million USD | -13.92% |
| 2018 Q4 | -8.79 Million USD | -39.48% |
| 2018 Q3 | -6.3 Million USD | 17.71% |
| 2018 Q2 | -7.65 Million USD | -5.88% |
| 2018 Q1 | -7.23 Million USD | -1.01% |
| 2017 Q1 | -6.01 Million USD | -6.84% |
| 2017 Q2 | -6.74 Million USD | -12.12% |
| 2017 Q3 | -6.39 Million USD | 5.13% |
| 2017 Q4 | -7.16 Million USD | -11.91% |
| 2017 FY | -26.32 Million USD | 5.38% |
| 2016 Q4 | -5.63 Million USD | 16.03% |
| 2016 Q1 | -7.21 Million USD | 14.03% |
| 2016 Q3 | -6.7 Million USD | 18.89% |
| 2016 Q2 | -8.26 Million USD | -14.64% |
| 2016 FY | -27.81 Million USD | 1.88% |
| 2015 Q2 | -6.49 Million USD | -1.69% |
| 2015 Q1 | -6.38 Million USD | -107.57% |
| 2015 FY | -28.34 Million USD | -93.55% |
| 2015 Q3 | -7.53 Million USD | -16.08% |
| 2015 Q4 | -8.38 Million USD | -11.3% |
| 2014 FY | -14.64 Million USD | -103.32% |
| 2014 Q2 | -3.45 Million USD | -93.77% |
| 2014 Q3 | -3.8 Million USD | -10.23% |
| 2014 Q4 | -3.07 Million USD | 19.14% |
| 2014 Q1 | -1.78 Million USD | 28.53% |
| 2013 Q3 | -2.01 Million USD | -24.5% |
| 2013 FY | -7.2 Million USD | 7.45% |
| 2013 Q4 | -2.49 Million USD | -23.86% |
| 2013 Q1 | -1.08 Million USD | 0.0% |
| 2013 Q2 | -1.61 Million USD | -49.08% |
| 2012 FY | -7.78 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | -155.56 Million USD | 146.714% |
| Theratechnologies Inc. | -10.62 Million USD | 783.815% |
| Safety Shot Inc | -12.18 Million USD | 696.422% |
| Cosmos Health Inc. | -21.83 Million USD | 432.867% |
| Cronos Group Inc. | -81.37 Million USD | 189.301% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 65.236% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 285.603% |
| Organogenesis Holdings Inc. | 12.52 Million USD | -480.192% |
| Universe Pharmaceuticals INC | -3.52 Million USD | 2160.495% |
| ProPhase Labs, Inc. | -21.61 Million USD | 436.228% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | 1645.82% |
| Dynavax Technologies Corporation | -37.02 Million USD | 296.254% |
| Radius Health, Inc. | -3.92 Million USD | 1951.439% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | 2989.174% |
| Alvotech | -354.86 Million USD | 120.478% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 1618.588% |
| Alpha Teknova, Inc. | -35.56 Million USD | 304.339% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 145.595% |
| Harrow Health, Inc. | 580 Thousand USD | -12429.138% |
| Biofrontera Inc. | -22.67 Million USD | 420.452% |
| DURECT Corporation | -36.88 Million USD | 297.02% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 1479.18% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | -54.71% |
| OptiNose, Inc. | -22.74 Million USD | 419.452% |
| RedHill Biopharma Ltd. | 12.63 Million USD | -475.277% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | 581.188% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | 1270.039% |
| SIGA Technologies, Inc. | 83.62 Million USD | 13.097% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | -678.791% |
| Shineco, Inc. | -17.06 Million USD | 525.815% |
| Phibro Animal Health Corporation | 53.31 Million USD | -36.301% |
| Procaps Group S.A. | 52.32 Million USD | -38.883% |
| TherapeuticsMD, Inc. | -8.52 Million USD | 952.622% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | 1634.161% |
| Viatris Inc. | 766.2 Million USD | 90.516% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 1618.588% |
| Rockwell Medical, Inc. | -6.67 Million USD | 1189.49% |
| Incannex Healthcare Limited | -30.04 Million USD | 341.899% |
| Aytu BioPharma, Inc. | -5.25 Million USD | 1483.118% |
| Tilray Brands, Inc. | -174.74 Million USD | 141.586% |
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 56.475% |
| PetIQ, Inc. | 60.01 Million USD | -21.085% |
| Silver Spike Investment Corp. | 7.34 Million USD | -890.026% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 71.037% |
| Journey Medical Corporation | -2.07 Million USD | 3605.499% |
| Alimera Sciences, Inc. | -1.47 Million USD | 5040.109% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | 633.65% |
| Assertio Holdings, Inc. | -243.53 Million USD | 129.839% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | 1333.271% |
| Embecta Corp. | 221.5 Million USD | 67.192% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 462.438% |
| Procaps Group, S.A. | 38.97 Million USD | -86.46% |
| PainReform Ltd. | -9.58 Million USD | 858.232% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 152.716% |
| Hempacco Co., Inc. | -8.81 Million USD | 924.633% |
| Talphera, Inc. | -16.88 Million USD | 530.274% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 17.115% |
| Alvotech | -354.86 Million USD | 120.478% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 80.071% |
| Kamada Ltd. | 10.06 Million USD | -622.069% |
| Indivior PLC | -4 Million USD | 1916.725% |
| Currenc Group, Inc. | -6.64 Million USD | 1193.46% |
| Evoke Pharma, Inc. | -7.43 Million USD | 1077.931% |
| Flora Growth Corp. | -50.35 Million USD | 244.316% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 462.438% |
| Evolus, Inc. | -49.23 Million USD | 247.602% |
| HUTCHMED (China) Limited | 18.37 Million USD | -295.478% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 63.11% |
| Akanda Corp. | -10.05 Million USD | 822.976% |